Table II.
List of differentially methylated genes overrepresented with cellular movement identified by IPA.
| UCSC_RefGene_Name | CHR | UCSC_RefGene_Accession | UCSC_RefGene_Group | Enhancer | Δβ* | P-value |
|---|---|---|---|---|---|---|
| FUT4 | 11 | NM_002033 | 1st Exon | TRUE | 0.1357 | 0.0000 |
| ITGB7 | 12 | NM_000889 | Body | 0.1622 | 0.0003 | |
| PRKAR1B | 7 | NM_001164759 | Body | 0.1125 | 0.0007 | |
| TRIP6 | 7 | NM_003302 | Body | 0.1091 | 0.0013 | |
| SPI1 | 11 | NM_001080547 | 3′UTR | TRUE | 0.1068 | 0.0014 |
| PLCB2 | 15 | NM_004573 | Body | TRUE | 0.1103 | 0.0018 |
| IL18 | 11 | NM_001562 | TSS200 | −0.1117** | 0.0019 | |
| SH2D3C | 9 | NM_005489 | Body; 5′UTR | 0.1227 | 0.0021 | |
| MAPK10 | 4 | NM_138980 | 5′UTR | TRUE | 0.1320 | 0.0034 |
| CLDN4 | 7 | NM_001305 | 1st Exon | TRUE | 0.1184 | 0.0060 |
| STAB1 | 3 | NM_015136 | Body | TRUE | 0.1012 | 0.0061 |
| PGLYRP2 | 19 | NM_052890 | Body | 0.1363 | 0.0078 | |
| CHAT | 10 | NM_001142929 | 1st Exon | TRUE | −0.1100 | 0.0111 |
| MAP4K1 | 19 | NM_001042600 | Body | 0.1534 | 0.0114 | |
| FGFR3 | 4 | NM_001163213 | Body | 0.1010 | 0.0129 | |
| FRZB | 4 | NM_001463 | 5′UTR; 1st Exon | TRUE | −0.1031 | 0.0132 |
| AIRE | 21 | NM_000383 | TSS200 | 0.1115 | 0.0134 | |
| ETS1 | 11 | NM_001143820 | Body | TRUE | 0.1198 | 0.0203 |
| PIP5K1C | 19 | NM_012398 | Body | 0.1270 | 0.0236 | |
| BMP4 | 14 | NM_130850 | Body | 0.1529 | 0.0263 | |
| JAK3 | 19 | NM_000215 | Body | TRUE | 0.1047 | 0.0316 |
| RIMS1 | 6 | NM_001168407 | TSS200; Body | −0.1357 | 0.0327 | |
| CD44 | 11 | NM_001001391 | TSS1500 | 0.1010 | 0.0494 |
AIRE: autoimmune regulator; BMP4: bone morphogenetic protein 4; CD44: cluster of differentiation 44; CHAT: choline acetyltransferase; CHR: chromosome; CLDN4: claudin-4; ETS1: v-ets avian erythroblastosis virus E26 oncogene homolog 1; FGFR3: fibroblast growth factor receptor 3; FRZB: frizzled-related protein; FUT4: fucosyltransferase IV; IL18: interleukin 18; ITGB7: intergrin, beta 7; JAK3: janus kinase 3; MAP4K1: mitogen-activated protein kinase kinase kinase kinase 1; MAPK10: mitogen-activated protein kinase 10; PGLYRP2: peptidoglycan recognition protein 2; PIP5K1C: phosphatidylinositol-4-phosphate 5-kinase, type I, gamma; PLCB2: phospholipase C, beta 2; PRKAR1B: protein kinase, cAMP-dependent, regulatory, type I, beta; RIMS1: regulating synaptic membrane exocytosis 1; SH2D3C: SH2 domain containing 3C; SPI1: spleen focus forming virus (SFFV) proviral integration oncogene; STAB1: stabilin 1; TRIP6: thyroid hormone receptor interactor 6; TSS: transcription start site; UCSC: University of California Santa Cruz; UTR: untranslated region.
*Δβ indicates the magnitude of mean methylation difference between control group and treatment group.
**Negative value indicates the reduced methylation level in treatment group compared with control group.